🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Diffuse Large B-cell Lymphoma (DLBCL)

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites📍 Beijing📍 Beijing📍 Beijing Xynomic Pharmaceuticals, Inc. · Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression NCT06005870Phase 21 site📍 Wuhan Huazhong University of Science and Technology · Tests: Zanubrutinib plus RCHOP Prospective ctDNA Testing in Large B-Cell Lymphoma NCT07878351n/a2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Standard-of-care first-line immunochemotherapy containing an anti-CD20 monoclonal antibody and an anthracycline, such a… Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites📍 Duarte📍 Sacramento📍 Tampa National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy NCT05757219Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site📍 Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. · Tests: Tafasitamab and Lenalidomide A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: ultra-fraction radiotherapy Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites📍 Bundang Gu📍 Seongnam-si📍 Gyeonggi-do Novartis Pharmaceuticals · Tests: Tisagenlecleucel A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma NCT06765317Phase 28 sites📍 Basking Ridge📍 Hackensack📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: Glofitamab, Polatuzumab, Rituximab, Cyclophosphamide, Doxorubicin A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma NCT07078500Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: orelabrutinib combined with the Pola-R-CHP regimen Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL NCT06832267NA1 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Los Angeles AVM Biotechnology Inc · Tests: AVM0703 Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site📍 Milan Incyte Biosciences Italy S.r.l A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients NCT06569485Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Trilaciclib+R-CHOP Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL NCT07493148Phase 21 site📍 Changchun Ou Bai, MD/PHD · Tests: Chidamide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT07197307Phase 234 sites📍 Aachen📍 Augsburg📍 Berlin Universität Münster · Tests: Loncastuximab Tesirine and Epcoritamab A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma NCT06683885Phase 1, Phase 21 site📍 Zhengzhou Mingzhi Zhang · Tests: Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma NCT03758989Phase 21 site📍 Rochester University of Rochester · Tests: Rituximab Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301Phase 19 sites📍 Duarte📍 Chicago📍 Grand Rapids Umoja Biopharma · Tests: UB-VV111, rapamycin Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652Phase 21 site📍 Monterrey Hospital Universitario Dr. Jose E. Gonzalez · Tests: Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) NCT07680933Phase 21 site📍 Xuzhou The Affiliated Hospital of Xuzhou Medical University · Tests: Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL NCT06803693Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma NCT06091865Phase 3194 sites📍 Scottsdale📍 Los Angeles📍 Orange Regeneron Pharmaceuticals · Tests: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine AZA Combined With RCHOP in P53-mutated DLBCL. NCT06158399Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Azacitidine in combination with R-CHOP Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL NCT07778212NA2 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Orelabrutinib Combined with Pola-R-CHP Regimen Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL NCT06503263Phase 21 site📍 Beijing Navy General Hospital, Beijing · Tests: Zanubrutinib plus Lenalidomide as Maintenance Therapy Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies NCT07270263NA1 site📍 Gdansk Medical University of Gdansk · Tests: Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy